Introduction The development of synthetic peptide generics derived from recombinant DNA (rDNA) originator products presents important analytical and regulatory challenges. […]
Introduction: Regulatory Support for generic drugs US and Canada CDMO services play a crucial role in helping pharmaceutical companies successfully
Introduction The Peptide Oligonucleotide Conjugates Mechanism of Action is based on combining a therapeutic oligonucleotide with a delivery peptide. The
Mechanism of Action of Peptide-Oligonucleotide Conjugates (POCs) Read More »
Introduction The Peptide Mapping Study of Semaglutide is an important analytical approach used during the development of synthetic peptide generics
Introduction: When developing a generic drug product, pharmaceutical companies must decide which type of external partner best fits their needs.
CDMO vs CRO for Generic Drug Development: Which Partner Do You Need? Read More »
Introduction Pharmaceutical companies often receive regulatory questions about nitrosamine impurities during submissions, variations, or post-approval reviews. When this happens, organizations
How to Respond to a Regulatory Query on Nitrosamine Risk Assessment Read More »
Introduction Peptide Oligonucleotide Conjugates Preclinical Services play an important role in supporting the development of Peptide Oligonucleotide Conjugates (POCs), which
Introduction: Analytical development for generic drugs Canada is a critical component of successful generic drug development and regulatory approval. Generic
Analytical Development Support from CDMOs for Generic Drug Projects Read More »
Introduction to QC Testing for Peptide Oligonucleotide Conjugates QC Testing for Peptide Oligonucleotide Conjugates is an essential analytical process used
Quality Control Testing for Peptide-Oligonucleotide Conjugates Read More »
Introduction: Outsourcing generic drug development Canada has become a strategic approach for pharmaceutical companies looking to accelerate market entry, reduce
Outsourcing Generic Drug Development in Canada: Why Pharma Companies Work with CDMOs Read More »
